The Clinical Research of Cytokine-induced Killer Cells Co-culturing with Autologous Dendritic Cells on the Clinical Immunotherapy for
Ning Zhu,Xiao-Dong Chen,Xiang-Lin Liu,Shang-Quan Zhang
DOI: https://doi.org/10.3969/j.issn.1674-7666.2008.02.024
2008-01-01
Abstract:It’s to investigate the cytotoxicity in vitro of cytokine-induced killer (CIK) cells after coculturing with autologous dendritic cells (DCs), and to observe their clinical antitumour efficacy, immunological activity, and side effects. Peripheral blood mononuclear cells (PBMC) were isolated from 12 patients with lung cancer, who had been treated with standard protocol. DCs and CIK cells were induced in vitro, then we determined the phenotype of cytokine-induced killer cells co-culturing with autologous dendritic cells (DCIK cells) and the cytotoxicity through MTT assay; when the ratios were 20∶1, 10∶1, the lysis ratios of DCIK cells were relatively 55%, 46.2%. All the patients were treated with a certain dosage of DCIK cells for immunotherapy, and we evaluated their clinical antitumour efficacy, immunological activity and side effects. Among the 12 patients, 1 patient got complete response, 4 patients got partial response and 1 patient got stable disease, so the recent clinical efficacy rate is 41.6%, and the rate of disease control is 50%. The other 6 patients got disease progressed, including that 2 patients died. The ratios of CD4+, CD8+, CD56+ significantly increased (P<0.05), comparing with ratios before DCIK cells infusion, which showed it could induce specific immunoreaction. No patient got side effect other than 2 patients who took a brief sensation of heat. DCIK cells is a new kind of killer cells , which could induce specific immunoreaction, and it could get better clinical efficacy.